SABCS: Combining ribociclib with hormone therapy improved patient outcomes in early-stage breast cancer
ABSTRACT: GA03-03
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease-free survival (iDFS) benefits in patients with early-stage hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer at risk of disease recurrence. Results from the Phase III NATALEE trial, led by researchers at The University of Texas MD Anderson Cancer Center, were presented...
SABCS: Studies suggest novel targeted therapies may benefit patients with metastatic HR+/ HER2- breast cancer
ABSTRACTS: RF01-04 and RF01-07
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical...
ESMO: Erdafitinib demonstrates improved responses in FGFR-altered advanced urinary tract cancers
ABSTRACTS: 2359O, 2362MO
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses...
ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
ABSTRACT: LBA41
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center. The...
MD Anderson names Christopher Flowers, M.D., Division Head of Cancer Medicine
The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, M.D., an internationally recognized physician-scientist...
MD Anderson announces new initiatives in Mozambique and Brazil to advance cancer prevention, treatment, research and education efforts
The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts in Mozambique and Brazil, including...
ASCO: Luspatercept enables majority of patients with MDS to end reliance on blood transfusions
ABSTRACT: 7003
Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin...
Andy Futreal and Helen Piwnica-Worms elected Fellows of the AACR Academy
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the 2023 class of Fellows of the American Association...
Florencia McAllister receives TAMEST Mary Beth Maddox Award for pancreatic tumor microbiome research
Florencia McAllister, M.D., associate professor of Clinical Cancer Prevention, Gastrointestinal Medical Oncology and Immunology at The University...
MD Anderson announces new collaboration in Indonesia to reduce global cancer burden
The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts through a new agreement with...